Chairs: Professor Michael Norton
Speakers: Scott McKenzie, Dr David Keeling
Supported by Pfizer Limited on behalf of the BMS-Pfizer Alliance
Anticoagulation in VTE: Is there an alternative way forward?
One of the greatest medical evolutions in the past decade has been the arrival of non-vitamin K antagonist oral anticoagulants (NOACs), revolutionising anticoagulation for stroke prevention in non-valvular atrial fibrillation, and the treatment and secondary prevention of venous thromboembolism (VTE).
NICE and EU guidelines recommend NOAC use as an option in VTE. With community-led management of deep-vein thrombosis, and British Thoracic Society guidelines recommending ambulatory care of low-risk patients with pulmonary embolism, NOACs offer flexibility for the diverse patients we manage.
Transitioning from traditional anticoagulation to NOACs is transforming the way patients engage with healthcare. In spite of this, NOAC uptake in VTE has been reserved and varies dramatically between clinical commissioning groups (CCGs).
Scott McKenzie, a change management consultant working with CCGs across the UK to enhance treatment pathways, will set the scene exploring efficiencies to be gained by using NOACs in VTE management. Dr David Keeling, a leading haematologist, will then update us on the latest data, bringing it to life and inspiring us to revaluate our clinical practice for the year ahead.
A Q&A session will follow in which the speakers welcome your input.
This sponsored satellite symposium has been organised and funded by Bristol-Myers Squibb/Pfizer, and contains promotional content